

**CLAIMS**

1. A method of using a modulator of glucocorticoid metabolism in the manufacture of a composition for the potentiation of a successful resolution of an inflammatory response in a mammal.
2. The method of claim 1, wherein the modulator increases the intracellular concentration of glucocorticoids in macrophages.
3. The method of claim 1, wherein the modulator is a modulator of the activity of an  $11\beta$ -HSD1 reductase enzyme.
4. An engineered macrophage having increased endogenous biosynthesis of active glucocorticoid.
5. The macrophage of claim 4, wherein the macrophage is genetically engineered.
6. The genetically engineered macrophage of claim 5, wherein endogenous  $11\beta$ -HSD1 activity is upregulated.
7. The macrophage of claim 4, for use in the potentiation of a successful resolution of the inflammatory response in a mammal.
8. A method of using a glucocorticoid or 11-dehydrocorticosteroid in the manufacture of a composition for the potentiation of a successful resolution of the inflammatory response in a mammal.
9. The method of claim 8, wherein the 11-dehydrocorticosteroid is activated by  $11\beta$ -HSD1.
10. The method of claim 8, wherein the glucocorticoid is administered in an inactive form.
11. The method of claim 10, wherein the inactive precursor of the glucocorticoid is a 11-dehydroxycorticosteroid.
12. A method of using a glucocorticoid or 11-dehydrocorticosteroid in the manufacture of a composition for the potentiation of a successful resolution of the inflammatory response in a mammal, wherein the composition further comprises a modulator of glucocorticoid metabolism according to claim 1.
13. A method of potentiating a successful resolution of the inflammatory response in a mammal, comprising administering to a mammal in need thereof a composition comprising a glucocorticoid or 11-dehydrocorticosteroid.

14. The method of claim 13, wherein the 11-dehydrocorticosteroid is activated by 11 $\beta$ -HSD1.

15. The method of claim 13, wherein the glucocorticoid is administered in an inactive form.

16. The method of claim 15, wherein the inactive precursor of the glucocorticoid is a 11-dehydroxycorticosteroid.

17. A method of potentiating a successful resolution of the inflammatory response in a mammal, comprising administering to a mammal in need thereof a composition comprising a glucocorticoid or 11-dehydrocorticosteroid, wherein the composition further comprises a modulator of glucocorticoid metabolism according to claim 1.

18. A pharmaceutical composition comprising a glucocorticoid in inactive form.

19. The pharmaceutical composition of claim 18, wherein the inactive precursor of the glucocorticoid is a 11-dehydroxycorticosteroid.

20. The pharmaceutical composition of claim 18, wherein the 11-dehydrocorticosteroid is activated by 11 $\beta$ -HSD1.

21. A pharmaceutical composition comprising a glucocorticoid in inactive form, wherein the composition further comprises a modulator of glucocorticoid metabolism according to claim 1.